Clinical Trials Logo

Filter by:
NCT ID: NCT05721300 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

Start date: February 10, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are: 1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment; 2. Repetitive effect and time effect of different drug treatment at different follow-up time points; 3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon; 4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination. Researchers will compare control group to see if occurrence of liver cancer.

NCT ID: NCT05721222 Recruiting - Clinical trials for Renal Cell Carcinoma

PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)

Start date: March 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors. Participants will have solid tumor or liquid cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This Phase 1/2 study will have two parts. Part A of the study will find out how much and how frequently PRO1160 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1160 is and if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC),Nasopharyngeal Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT05721144 Completed - COVID-19 Clinical Trials

Inhaled NO in Surgical Patients With Recent COVID-19 Infection

INORDINATE
Start date: February 17, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the effect of perioperative inhalation of NO on reducing the incidence of postoperative pulmonary complications in patients with recent COVID-19 infection, and to evaluate whether inhaled NO can improve the prognosis of patients. The investigators will enroll 660 surgical patients who was infected with SARS-CoV-2 within 42days (7 weeks ) prior to planed surgery under general anesthesia. Patients will be randomized to receive either inhaled nitric oxide (per protocol) or a placebo. Perioperative standards of care will be the institution's own protocols (such as ventilation strategies and use and dose of anesthetics, analgesia and fluid management, etc).

NCT ID: NCT05720845 Not yet recruiting - Lung Disorder Clinical Trials

Effects of Different Ventilatory Strategy on Intraoperative Atelectasis During Bronchoscopy Under General Anesthesia.

Start date: February 8, 2023
Phase: N/A
Study type: Interventional

This trial compares two different types of ventilation for the prevention of partial or complete collapsed lung (atelectasis) in patients undergoing interventional pulmonology procedures under general anesthesia. Ventilatory strategy to prevent reduce the intra-procedural development of atelectasis during interventional pulmonology procedures under general anesthesia.

NCT ID: NCT05720754 Not yet recruiting - Dry Eye Clinical Trials

Temperature on Evaporative Dry Eye

Start date: April 2, 2023
Phase: N/A
Study type: Interventional

Ocular surface temperature of a normal person is around 34.6 degree centigrade. After instilling the eye drop, depending on the temperature of the eye drop and the ocular surface, the ocular surface temperature will temporally increase or decrease sightly. Warm feeling will make blood vessels dilated and more blood will pass through to bring more blood flow out of our body to the heated area of the body and makes cells more permeable. Therefore, heating the ocular surface with heated eye mask after instilling artificial tears has the possibility to improve drug permeability on the ocular surface.

NCT ID: NCT05720650 Withdrawn - Preeclampsia Clinical Trials

B Vitamin Deficiency and Pregnancy Complications

Start date: June 1, 2023
Phase:
Study type: Observational

This case-control study aims to investigate the association between B vitamins and gestational hypertension or preeclampsia.

NCT ID: NCT05720637 Completed - Clinical trials for Major Depressive Disorder

The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is highly prevalent, affecting nearly 4% of the global population. Pharmacotherapy is the frontline treatment recommended by the guideline, but it also has some limitations such as delayed onset, inadequate response, and drug resistance. Intradermal acupuncture (IA) is a method of using short indwelling needles retained under the skin to produce continuous stimulation for long-term efficacy. It has been reported that IA combination medication appears to be more valuable than medication alone in the treatment of MDD, however, there is a lack of high-quality clinical evidence.While several studies have proposed that manual or electroacupuncture can improve MDD symptoms by modulating brain networks, the cerebral mechanism of IA as superficial acupuncture for MDD has not been reported. Hence, investigators designed a multicentre randomized controlled trial to assess the clinical efficacy and safety of IA for MDD and preliminarily explore the potential therapeutic mechanisms for IA by functional magnetic resonance imaging (fMRI) .

NCT ID: NCT05720299 Recruiting - Clinical trials for Obesity Associated Disorder

A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila on Insulin Resistance Among Obese Subjects.

Start date: March 29, 2023
Phase: N/A
Study type: Interventional

In this study, the drug Akkermania muciniphila has been proved to play an important role in the occurrence and development of obesity related metabolic diseases. The purpose of this study was to evaluate the safety and efficacy of AKK in the treatment of insulin resistance related obesity. In this study, a single center, randomized, double-blind, placebo-controlled design was adopted. 120 patients with obesity related to insulin resistance were included in this study, and were allocated to live bacteria high-dose group, live bacteria low-dose group, and placebo group at a ratio of 1:1:1. The study lasted for 12 weeks. The changes of body fat, glucose metabolism, lipid metabolism indicators, and fatty liver changes compared with the baseline at the end of the treatment were analyzed. In addition, glucagon like peptide-1 (GLP-1) in plasma and inflammatory markers (hsCRP, TNF) in blood will be analyzed before and after treatment- α、 IL-6、IL-8、IL-1 β) Level, plasma LPS level, oxygen/hydrogen/methane level in methane hydrogen breath test, changes in fecal flora structure, and the mechanism of AKK bacteria affecting insulin resistance by analyzing bacterial metabonomics molecular spectrum in plasma and urine.

NCT ID: NCT05720273 Recruiting - Clinical trials for Chronic Kidney Disease-Mineral and Bone Disorder

Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients

NGAL
Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this observational study or clinical trial is to learn about the effect of neutrophil gelatinase-associated lipocalin (NGAL) on vascular calcification in maintenance hemodialysis patients with secondary hyperparathyroidism (SHPT). The main question it aims to answer is: the predictive effects of blood NGAL level on the efficacy of palicalcitol in the treatment of SHPT and the adverse reactions of vascular calcification progression. Participants will be treated with palicalcitol, followed up and undergo routine series of Chronic Kidney Disease-Mineral and Bone Disorder associated tests before and after treatment.

NCT ID: NCT05720234 Recruiting - Clinical trials for Severe Aplastic Anemia

Avatrombopag Combined With IST as First-line Treatment for SAA

Start date: November 10, 2022
Phase: Phase 2
Study type: Interventional

This single-center study aims to evaluate the early efficacy and safety of avatrombopag combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic anemia (SAA).